Last Price
0.138
Today's Change
+0.012 (9.52%)
Day's Change
0.123 - 0.138
Trading Volume
2,416,507
Overview
Market Cap
14 Million
Shares Outstanding
108 Million
Avg Volume
4,047,432
Avg Price (50 Days)
0.17
Avg Price (200 Days)
0.51
PE Ratio
-0.92
EPS
-0.15
Earnings Announcement
27-Mar-2025
Previous Close
0.13
Open
0.13
Day's Range
0.1225 - 0.138
Year Range
0.105 - 4.54
Trading Volume
2,416,507
Price Change Highlight
1 Day Change
9.54%
5 Day Change
14.83%
1 Month Change
-12.17%
3 Month Change
-35.91%
6 Month Change
-81.50%
Ytd Change
-85.01%
1 Year Change
-96.64%
3 Year Change
-98.61%
5 Year Change
-98.61%
10 Year Change
-98.61%
Max Change
-98.61%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
NordFX Weekly Forecast
Forex and Cryptocurrency Forecast for September 09 – 13, 2024
2
CEO Morning Brief
Ultra-rich Families Set to Control US$9.5 Tril by 2030, Says Deloitte
3
CEO Morning Brief
4
CEO Morning Brief
5
CEO Morning Brief
US Trade Deficit Widens to US$78.8 Bil, Largest in Two Years
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
